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Ischaemic heart disease is becoming an increasingly
frequent cause of ischaemic mitral regurgitation
(IMR). Three different clinical entities of IMR,
which deeply affect the clinical decision making,
are distinguishable: the acute IMR complicating an
acute myocardial infarction, the true IMR second-
ary to a transient ischaemic phenomenon, and the
chronic functional IMR (FIMR). The incidence of
the two first entities is low; the third is much more
frequent.
ACUTE ISCHAEMIC MITRAL REGURGITATION
COMPLICATING THE ACUTE PHASE OF
MYOCARDIAL INFARCTION
IMR can occur acutely in patients sustaining an
acute myocardial infarction. The rupture of a
papillary muscle—most frequently a head of a
posteromedial papillary muscle—is a dramatic
mechanical complication of acute myocardial
infarction, leading to a very high mortality rate
in the absence of immediate surgical intervention.
Surgery, most often valve replacement, is war-
ranted after stabilisation of the haemodynamic
status using an intra-aortic balloon pump and
vasodilators.1 In the absence of such a rupture, the
presence of IMR in the acute myocardial infarction
phase portends a grave prognosis. Its incidence and
clinical importance are largely underestimated,
partly because physical examination is rather
insensitive. Prompt in-hospital revascularisation
can prevent or reverse acute IMR.2 When limited
to the inferior wall, early revascularisation may
reduce localised left ventricular (LV) remodelling
and IMR.3 Early revascularisation also increases
survival in patients with acute IMR presenting
with shock.4
TRUE ISCHAEMIC MITRAL REGURGITATION
This second form truly defines IMR because it is
secondary to an active ischaemic episode. It is
clinically most often revealed by a ‘‘whistling
angina‘‘ or a ‘‘flash pulmonary oedema’’.5 It is
linked to the presence of a significant stenosis of
the right or left circumflex coronary artery. In this
situation, the primary treatment is to prevent the
episodes of active myocardial ischaemia by a
revascularisation procedure.
CHRONIC FUNCTIONAL ISCHAEMIC MITRAL
REGURGITATION
Chronic FIMR, the most common cause of IMR,
broadly denotes abnormal function of normal
leaflets in the context of impaired ventricular
function resulting from ischaemic heart disease. It
results from an imbalance between tethering forces
(annular dilatation, LV dilatation, papillary mus-
cles displacement, LV sphericity) and closing forces
(reduction of LV contractility, global LV dyssyn-
chrony, papillary muscle dyssynchrony, altered
mitral systolic annular contraction).5 Chronic
FIMR results, in 95% of cases, from a type IIIb
dysfunction (restricted leaflet motion). It is impor-
tant to note that in the remaining 5%, an
ischaemic elongation of the papillary muscle may
cause prolapse in the corresponding area (type II
dysfunction). When present, FIMR may exhibit a
broad range of severity and, when severe (effective
regurgitant orifice (ERO) >20 mm2), conveys a
poor outcome. FIMR is characteristically dynamic
during exercise. It has been shown that an increase
(DERO >13 mm2) in FIMR during exercise identi-
fies a subgroup of patients at higher risk of cardiac
events.6 7
MANAGEMENT OF FUNCTIONAL ISCHAEMIC
MITRAL REGURGITATION
When treating FIMR, it is important to integrate
several clinical parameters—symptoms of heart
failure, episodes of worsening heart failure, comor-
bidities—and echocardiographic elements—mitral
regurgitation severity at rest and its dynamic
nature at exercise, the degree of mitral valve
apparatus deformation, the origin and direction
of regurgitant jets, the importance of LV remodel-
ling, the presence of LV dyssynchrony, the
presence and extent of viable myocardium at
jeopardy. Different clinical scenarios might thus
largely modulate the clinical decision making.
Practically, instead of medical treatment, un-
balanced tethering can be addressed by mitral
valve surgery or by LV reshaping, whereas coronary
revascularisation or cardiac resynchronisation ther-
apy can potentially reduce tethering as well as
increase mitral valve closing forces (fig 1).
Medical treatment
The scope of medical treatment, which remains the
first step in the management of these patients, is to
prevent myocardial ischaemia, reduce the severity
of FIMR, and revert or delay the LV remodelling
process. However, presently no pharmacological
approach has been shown to improve the patient
clinical outcome. Usual medical treatment of heart
failure, including angiotensin converting enzyme
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(ACE) inhibitors, b-blockers and spironolactone,
should be prescribed according to the official
recommendations. All these drugs gradually lead to
a fundamental reshaping of the LV. Diuretics are
administered according to the signs of water reten-
tion. In cases of acute dyspnoea, sublingual nitrates
seem to be beneficial. In practice, FIMR appears to
remain common despite the use of these drugs.8
Cardiac resynchronisation therapy
Currently, when a revascularisation procedure is
not indicated or insufficient to improve the clinical
status, the use of biventricular pacing is justified
(European Society of Cardiology (ESC) guidelines
class I level of evidence A) in heart failure patients
with significant ventricular conduction delay (QRS
.120 ms) who remain symptomatic despite opti-
mal drug treatment.9 The effects of cardiac
resynchronisation therapy (CRT) on FIMR can be
observed acutely or only late after implantation.
This treatment is associated with an immediate
reduction in the quantified degree of FIMR
(expected reduction of 35%), which is directly
correlated to the improvement in LV systolic
performance (greater mitral closing force)—
increase in LV dP/dt—and the reduction in the
interpapillary muscle activation time delay (less
tension on mitral leaflets).10 11 Reduction in mitral
regurgitation severity also results from a more
effective mitral annulus contraction and a signifi-
cant decrease in systolic tenting area—the systolic
displacement of the body of the mitral leaflets into
the LV cavity. Thus, in the acute stage, CRT
corrects the imbalance between forces acting on
the mitral valve and enhances the sphincteric
action of the annulus. It should be noted that
these changes are often insufficient to remove
regurgitation. Persistent residual FIMR is deter-
mined by the extent of residual deformation of the
mitral valve.12
Besides these acute effects, an additional 10–20%
reduction in FIMR, that parallels the decrease in LV
volumes and the increase in LV dP/dt, occurs some
months after CRT. Although this improvement is
sustained at 1 year follow-up, it could be attenu-
ated in some patients secondary to the progression
of the ischaemic disease.13 The benefit of CRT
appears to be dependent on continued pacing
because withholding pacing results in an immedi-
ate loss of efficacy and recurrence of FIMR. Indeed,
the transient interruption of CRT after long term
results in acute deterioration of FIMR as a
consequence of a pronounced decline in LV dP/dt
and the reappearance of significant papillary
muscle dyssynchrony.14 This supports the notion
of maintaining CRT indefinitely. The effect of
CRT on dynamic FIMR is also progressive and
appears in the chronic stage of stimulation. Indeed,
CRT reduces not only FIMR at rest but also its
dynamic component during exercise. The expected
attenuation of exercise induced FIMR is about
30%.12 15 However, CRT reduces the amount of
increase in FIMR but does not avoid the develop-
ment of at least some dynamic component in most
patients.
The response to CRT might be modulated by the
severity of FIMR and the extent of LV remodelling
before implantation. Severe FIMR (ERO>20 mm2)
in the setting of an enlarged LV is associated with
lack of reverse remodelling during follow-up.
Patients with more severe disease are thus less
likely to respond to CRT. Moreover, the degree to
which the reduction in FIMR plays a role in reverse
LV remodelling remains currently unclear. CRT
reduces but does not abolish FMR in most patients.
The persistence of a critical level of regurgitation
might thus be able to perpetuate the LV remodel-
ling process. Data concerning long term effects are
limited. Importantly, this mode of treatment is
restricted to patients who fulfil the classical criteria
for CRT.
Surgical treatment
The indication for surgical correction of FIMR is a
source of debate. In most cases, coronary bypass
grafting alone is not sufficient to remove regur-
gitation or even to reduce its severity.16 However,
Figure 1 Global management of functional ischaemic mitral regurgitation.
ACE, angiotensin converting enzyme; CABG, coronary artery bypass grafting;
CRT, cardiac resynchronisation therapy; ERO, effective regurgitant orifice;
FIMR, functional ischaemic mitral regurgitation; HF, heart failure; ICD, implantable
cardioverter-defibrillator; LV, left ventricle; MV, mitral valve; PCI, percutaneous coronary
intervention.
Table 1 Indications for surgery in ischaemic mitral regurgitation (IMR)
Clinical situation Mitral valve surgery (ESC guidelines 2007)
Patients with severe IMR (ERO >20 mm2)
Ruptured papillary muscle due to acute MI Immediate
LV ejection fraction >30% undergoing CABG Recommended (IC)
LV ejection fraction ,30% and option for CABG Reasonable if symptomatic (IIaC)
LV ejection fraction >30%, no option for CABG To consider if symptomatic and low morbidity
(IIbC)
Patients with moderate IMR (ERO ,20 mm2)
Undergoing CABG Reasonable if repair is feasible (IIaC)
No option for CABG or undergoing PCI Uncertain (‘‘a priori not’’)
Patients with trace IMR
Undergoing CABG Not recommended
CABG, coronary bypass grafting; ERO, effective regurgitant orifice; ESC, European Society of Cardiology; LV, left
ventricular; MI, myocardial infarction; PCI, percutaneous coronary intervention.
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not treating FIMR exposes the patient to a higher
risk of hospitalisation for heart failure.17 The
possible survival impact of mitral valve surgery is
poorly known; mortality at 5 years remains high.18
Results from the literature unfortunately reflect
their retrospective nature, the inevitable patient
selection bias, and unresolved issues such as the
best surgical technique to use. So far, the added
value of valve repair compared to bypass surgery
alone is thus uncertain. Table 1 lists the indications
for surgery, and table 2 the predictors of outcome
following surgery.
Practically, the decision to intervene in the
mitral valve will depend on the severity of FIMR
and whether or not bypass grafting will be
scheduled. Unanimously, severe FIMR (ERO
>20 mm2) should be corrected at the time of
bypass surgery (ESC level IC),8 while trivial FIMR
(ERO ,10 mm2) can be neglected. Remodelling
annuloplasty using a prosthetic undersized ring
(one or two sizes) is the technique of choice in type
IIIb dysfunction.19 If the repair is unfeasible
(limited cases) or there is type II dysfunction in
which stringent annuloplasty will be often ineffi-
cient, it is reasonable to advocate mitral valve
replacement (bioprosthesis) with preservation of
the subvalvular apparatus. In symptomatic
patients with severe FIMR and no option for
revascularisation, mitral valve repair may be
considered (ESC level IIbC). However, when the
LV function is severely impaired, surgery is more
likely to be considered if myocardial viability is
present, if comorbidity is low, if FIMR increases
dynamically during exercise, if the LV is not
severely remodelled, and if the revascularisation
can be almost complete. In the other cases, cardiac
transplantation (ESC level IC) remains the prefer-
able approach since it is associated with a better
5 year outcome (fig 2).
In patients with moderate FIMR (ERO
,20 mm2), the ischaemic symptoms usually dic-
tate the treatment strategy. For example, mildly
symptomatic patients with no residual myocardial
ischaemia and mild to moderate FIMR will be
usually treated medically, whereas symptomatic
patients with active or inducible ischaemia will be
oriented towards a revascularisation procedure.
When percutaneous coronary revascularisation is
performed, mitral valve surgery is rarely proposed.
In this situation, the patient should be carefully
followed up to detect any FIMR progression and
ongoing LV remodelling process. Conversely, when
bypass grafting is planned, the decision to repair
the mitral valve remains a matter of controversy.
In such cases, if the mitral valve is repairable,
combined surgery is reasonable (ESC level IIaC).
However, the additional risk of mitral valve
surgery is not negligible, particularly in patients
with comorbidities and poor LV function. Very ill
patients should be treated conservatively with
revascularisation alone.17 In the future percuta-
neous annuloplasty may possibly be proposed for
these patients.20 Low risk patients can be further
stratified with exercise echocardiography.16
Although this technique is of growing interest, its
value to predict the results of surgery still remains
to be evaluated. Patients with a dynamic increase
in FIMR (DERO >13 mm2) during exercise might
be submitted for combined surgery, while patients
with either no significant changes or exercise
induced reduction in FIMR as a result of recruitable
function in the inferobasal wall might be referred
for bypass grafting alone (fig 3).
Several groups have used transoesophageal echo-
cardiography at the beginning of the intervention
to make this decision. However, because of
changes in loading conditions, general anaesthesia
leads almost systematically to underestimation of
FIMR severity (reduction of moderate FIMR to
trace amounts).21 Accordingly, to minimise the
effects of anaesthetic induction on FIMR some
groups perform a preload and afterload challenge
test. A rapid fluid filling is performed until
the mean capillary wedge pressure reaches
15–18 mm Hg. If the regurgitation does not
Table 2 Predictors of outcome after mitral valve surgery
History Condition Echocardiography Surgery
Older age LV ejection fraction ,30%
Diabetes mellitus High Euroscore Extensive scar + no viability Left main stenosis
Cardiac heart failure Emergent operation Severe LV remodelling Three vessel disease
Increasing NYHA class Cardiogenic shock Severe MV deformation MV replacement
Renal failure Complex regurgitant jet Residual IMR
Associated diseases Restrictive diastolic filling
IMR, ischaemic mitral regurgitation; LV, left ventricular; MV, mitral valve; NYHA, New York Heart Association.
Figure 2 Management of patients with severe functional ischaemic mitral regurgitation.
CABG, coronary artery bypass grafting; CRT, cardiac resynchronisation therapy;
EDD, end-diastolic diameter; EF, ejection fraction; ERO, effective regurgitant orifice;
ICD, implantable cardioverter-defibrillator; LV, left ventricle; MV, mitral valve; MVS, mitral
valve surgery; PL WM, posterolateral wall motion.
Education in Heart
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increase, phenylephrine is administered until the
mean arterial blood pressure reaches
100 mm Hg.18 21 This approach provides a rough
assessment of the dynamic behaviour of FIMR.
Indeed, the level of increase in the FIMR associated
with the need for repair is not yet validated.
Practically, it is probably best to identify potential
candidates for combined surgery before interven-
tion.
Residual or recurrent FIMR after mitral valve surgery
It has become increasingly clear that a ventricular
problem cannot be resolved by a single annular
procedure—that does not directly address tethering
by the remodelled LV—in every case.5 Persistence
or recurrence of FIMR is observed in approximately
one third of patients, the risk being more sig-
nificant during the first 6 months after surgery
(table 3).5 16 The persistence of FIMR—which can
perpetuate the LV remodelling process and
adversely affect the patient’s outcome—could be
explained by the postoperative persistence and/or
worsening of mitral leaflets tethering.5 In most
instances, mitral ring annuloplasty reduces the
anterior–posterior annular dimension and contri-
butes to restoring a surface of coaptation.19 By
doing so, it always induces, for geometrical reasons,
a further tethering of the posterior leaflet, but also
of the anterior leaflet, and frequently converts the
valve into a monocusp with sometimes a restricted
anterior leaflet motion as well.22 This pattern of
coaptation of the edge of the anterior leaflet against
the body of the even more tethered posterior leaflet
usually accounts for a mild residual leak post-
operatively. This is particularly more pronounced in
patients with an asymmetrical mitral orifice (P2–P3
are more restricted) who received a symmetrical
ring. If the remodelling process is not halted by the
procedure, a further tethering of both the anterior
and posterior leaflet is expected with a recurrence of
FIMR.5
Several echocardiographic parameters can help to
identify patients at risk of treatment failure (fig 4).
Preoperatively (transoesophageal echocardiogra-
phy), patients with a mitral diastolic annulus
diameter >37 mm, a systolic tenting area
>1.6 cm2 and an FIMR grade .3.5 have a 50%
probability of failure during follow-up.23
Preoperatively (transthoracic echocardiography), a
coaptation distance .1 cm (distance between the
leaflet coaptation point and the mitral annulus
plane in the apical four chamber view), a systolic
tenting area .2.5 cm2 (the area enclosed between
the annular plane and mitral leaflets in the
parasternal long axis view), a posterior leaflet
angle >45u (indicating a high posterior leaflet
Figure 3 Management of patients with moderate functional ischaemic mitral
regurgitation. CABG, coronary artery bypass grafting; CRT, cardiac resynchronisation
therapy; ERO, effective regurgitant orifice; FIMR, functional ischaemic mitral
regurgitation; ICD, implantable cardioverter-defibrillator; LV, left ventricle; MV, mitral
valve; NYHA, New York Heart Association; PCI, percutaneous coronary intervention;
PL, posterolateral.
Table 3 Preoperative predictors of mitral valve repair
failure (transthoracic echocardiography)
Parameters Threshold
Coaptation distance >1 cm
Systolic tenting area .2.5–3 cm2
Posterolateral angle >45u
Lateral wall motion abnormality Scar
Central regurgitant jet –
Complex regurgitant jets Multiple
Left ventricular end-diastolic diameter >65 mm
Left ventricular end-systolic diameter >51 mm
Figure 4 Echocardiographic assessment of mitral valve deformation. CD, coaptation
distance (red arrow); PLA, posterior leaflet angle; PLL, posterior leaflet length (green
arrow).
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restriction), a central regurgitant jet (indicating a
severe restriction of both leaflets in patients with
severe FIMR), the presence of complex jets
originating centrally and posteromedially, a restric-
tive diastolic filling profile (suggesting a more
advanced LV disease process and associated with
further negative LV remodelling after repair), and a
severe LV enlargement (low likelihood of reverse
LV remodelling after repair and poor late outcome)
increase the risk of mitral valve repair failure.
Taking these parameters altogether could reduce
the frequency of postoperative FIMR.24 For exam-
ple, using a two sizes stringent ring (ring 24–26), in
conjunction with obtaining a coaptation distance
(8 mm at the end of intervention in selected
patients with a preoperative LV end diastolic
volume (65 mm, leads to a dramatic decrease in
the incidence of recurrent FIMR as low as 2.3%.18
This could, however, increase the risk of inducing
mitral stenosis.25 When the mitral valve is severely
deformed and the LV significantly enlarged, it
would be reasonable also to restore the geometry of
the LV and/or to reduce directly the leaflets
tethering by a complementary subvalvular or
ventricular approach. In some cases, mitral valve
replacement is defendable.
New treatment modalities
This intrinsic limitation of simple reductive annu-
loplasty has been challenged by different techni-
ques which aim at reducing the traction exerted
from the LV on the mitral valve.26 Enlargement of
the posterior leaflet, especially in the area of the
posteromedial commissure, may enable the place-
ment of a normal ring and restore a surface of
coaptation by reducing the tethering. The surgical
relocation of the posterior papillary muscle is
another approach to correct the tethering at the
ventricular level.27 Resection of secondary strut
cords that account in some cases for bending of the
anterior leaflet and reduced coaptation, although
appealing, has not led to conclusive clinical
results.28 The association of the edge-to-edge
Alfieri procedure to an undersized annuloplasty
seems to reduce the incidence of repair failure in
patients with excessive tethering (coaptation dis-
tance >1 cm).29 Asymmetrical tethering could be
solved by using an asymmetrical ring annuloplasty.
Severe LV remodelling could be challenged by an
LV restoration using the modified Dor procedure or
by applying the ‘‘Acorn’’ or the ‘‘Myosplint’’
system.30
More recently, various companies have launched
studies on percutaneous approaches of mitral valve
repair. The majority of devices (for example,
MitraLife-Edwards, Edwards Monarc, Cardiac
Dimensions, Viacor) take advantage of the proxi-
mity of the coronary sinus to the posterior mitral
annulus to deliver devices (anchors that are placed
in the anterior and posterior portions of the
coronary sinus) that remodel the mitral annu-
lus.31–33 The Edwards Monarc device consists of a
pair of self expanding nitinol anchoring stents
located at the ends of the device and joined to each
other by a connecting element that undergoes
delayed shortening over 3–4 weeks after place-
ment. The Cardiac Dimensions Carillon device
consists of two different sized, self expanding
figure-of-eight nitinol loops located at either end of
a fixed length stainless steel connector. The Viacor
device is used to place one or more straightening
rods within a catheter that is positioned in the
coronary sinus via the subclavian vein. Although
these rods do not plicate the coronary sinus per se,
they do ‘‘bend’’ the sinus in a manner that pushes
the posterior leaflet forward relative to the location
of the commissures. Other devices such as the
Mitralign perform septal lateral cinching by direct
placement of several almost-stapled-like anchors
around the mitral annulus to reduce the diameter
of the orifice. The percutaneous septal sinus
shortening approach (Ample Medical), the
Quantun Cor, and the minimally invasive
iCoapsys device are new percutaneous devices
under evaluation. Finally, in an experimental
model, it has been shown that cell transplantation
in the infarcted area can also potentially reduce
IMR through a decrease in localised LV wall
How to manage ischaemic mitral regurgitation: key points
c Bypass grafting (CABG) alone does not correct functional ischaemic mitral
regurgitation (FIMR) in most patients.
c The candidate for combined surgery (mitral valve replacement + CABG)
should be selected preoperatively.
c Undersized mitral annuloplasty is the technique of choice.
c Recurrent FIMR is frequent in patients with severe mitral valve deformation/
left ventricular remodelling.
c Survival advantage from repair rather than mitral valve replacement is evident
in most patients.
c The precise role of subvalvular adjuncts needs to be studied.
c Prospective registries and randomised trials are necessary.
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deformation.34 So far, these techniques—which
stress the importance of addressing the ventricular
factors that cause FIMR—have only been applied
in small clinical cohorts or are still limited to
experimental models. Thus, definitive recommen-
dations cannot be made at present.
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